C. Ananth, K. Keyes, and R. Wapner, Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis, BMJ, vol.347, issue.nov07 15, p.6564, 2013.
DOI : 10.1136/bmj.f6564

S. Karumanchi, S. Maynard, I. Stillman, F. Epstein, and V. Sukhatme, Preeclampsia: A renal perspective, Kidney International, vol.67, issue.6, pp.2101-2113, 2005.
DOI : 10.1111/j.1523-1755.2005.00316.x

URL : http://doi.org/10.1111/j.1523-1755.2005.00316.x

J. Barton and B. Sibai, Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome, Clinics in Perinatology, vol.31, issue.4, pp.807-833, 2004.
DOI : 10.1016/j.clp.2004.06.008

B. Sibai, M. Ramadan, I. Usta, M. Salama, B. Mercer et al., Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome), American Journal of Obstetrics and Gynecology, vol.169, issue.4, pp.1000-1006, 1993.
DOI : 10.1016/0002-9378(93)90043-I

S. Cavkaytar, E. Ugurlu, A. Karaer, O. Tapisiz, and N. Danisman, Are clinical symptoms more predictive than laboratory parameters for adverse maternal outcome in HELLP syndrome?, Acta Obstetricia et Gynecologica Scandinavica, vol.86, issue.6, pp.648-651, 2007.
DOI : 10.1080/00016340601185384

B. Sibai, Diagnosis, Controversies, and Management of the Syndrome of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count, Obstetrics & Gynecology, vol.103, issue.5, Part 1, pp.981-991, 2004.
DOI : 10.1097/01.AOG.0000126245.35811.2a

N. Selçuk, A. Odabas, R. Cetinkaya, H. Tonbul, and A. San, OUTCOME OF PREGNANCIES WITH HELLP SYNDROME COMPLICATED BY ACUTE RENAL FAILURE (1989???1999), Renal Failure, vol.280, issue.6, pp.319-327, 1989.
DOI : 10.1001/jama.280.6.559

K. Abraham, M. Kennelly, A. Dorman, and J. Walshe, Pathogenesis of acute renal failure associated with the HELLP syndrome: a case report and review of the literature, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.108, issue.1, pp.99-102, 2003.
DOI : 10.1016/S0301-2115(02)00352-4

J. Ibdah, M. Bennett, R. P. Zhao, Y. Gibson, B. Sims et al., A Fetal Fatty-Acid Oxidation Disorder as a Cause of Liver Disease in Pregnant Women, New England Journal of Medicine, vol.340, issue.22, pp.1723-1731, 1999.
DOI : 10.1056/NEJM199906033402204

T. Knox and L. Olans, Liver Disease in Pregnancy, New England Journal of Medicine, vol.335, issue.8, pp.569-576, 1996.
DOI : 10.1056/NEJM199608223350807

V. Fremeaux-bacchi, F. Fakhouri, A. Garnier, F. Bienaimé, M. Dragon-durey et al., Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults, Clinical Journal of the American Society of Nephrology, vol.8, issue.4, pp.554-562, 2013.
DOI : 10.2215/CJN.04760512

F. Fakhouri, L. Roumenina, F. Provot, M. Sallée, S. Caillard et al., Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations, Journal of the American Society of Nephrology, vol.21, issue.5, pp.859-867, 2010.
DOI : 10.1681/ASN.2009070706

URL : https://hal.archives-ouvertes.fr/hal-00512540

M. Moatti-cohen, C. Garrec, M. Wolf, P. Boisseau, L. Galicier et al., Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura, Blood, vol.119, issue.24, pp.5888-5897, 2012.
DOI : 10.1182/blood-2012-02-408914

J. Martin, A. Bailey, J. Rehberg, M. Owens, and S. Keiser, Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006, American Journal of Obstetrics and Gynecology, vol.199, issue.2, pp.98-104, 2008.
DOI : 10.1016/j.ajog.2008.03.011

M. Scully, M. Thomas, M. Underwood, H. Watson, K. Langley et al., Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes, Blood, vol.124, issue.2, pp.211-219, 2014.
DOI : 10.1182/blood-2014-02-553131

URL : http://www.bloodjournal.org/content/bloodjournal/124/2/211.full.pdf

K. Hovinga, J. Vesely, S. Terrell, D. Lämmle, B. George et al., Survival and relapse in patients with thrombotic thrombocytopenic purpura, Blood, vol.115, issue.8, pp.1500-1511, 2010.
DOI : 10.1182/blood-2009-09-243790

URL : http://www.bloodjournal.org/content/bloodjournal/115/8/1500.full.pdf

Y. Benhamou, P. Boelle, B. Baudin, S. Ederhy, J. Gras et al., Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center, Journal of Thrombosis and Haemostasis, vol.7, issue.2, pp.293-302, 2015.
DOI : 10.1371/journal.pone.0038573

URL : http://onlinelibrary.wiley.com/doi/10.1111/jth.12790/pdf

G. Hanouna, N. Morel, L. T. Huong, D. Josselin, L. Vauthier-brouzes et al., Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases, Rheumatology, vol.52, issue.9, pp.1635-1641, 2013.
DOI : 10.1093/rheumatology/ket167

S. Maynard, J. Min, J. Merchan, K. Lim, J. Li et al., Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, Journal of Clinical Investigation, vol.111, issue.5, pp.649-658, 2003.
DOI : 10.1172/JCI17189

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151901/pdf

S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto et al., Soluble endoglin contributes to the pathogenesis of preeclampsia, Nature Medicine, vol.274, issue.6, pp.642-649, 2006.
DOI : 10.1161/01.ATV.10.4.653

A. Hertig, J. Fort, G. Lefevre, N. Chabbert-buffet, M. Uzan et al., Soluble endoglin in preeclamptic patients with or without HELLP syndrome, American Journal of Obstetrics and Gynecology, vol.202, issue.6, pp.594-591, 2010.
DOI : 10.1016/j.ajog.2010.03.006

M. Noris, M. Galbusera, S. Gastoldi, P. Macor, F. Banterla et al., Dynamics of complement activation in aHUS and how to monitor eculizumab therapy, Blood, vol.124, issue.11, pp.1715-1726, 2014.
DOI : 10.1182/blood-2014-02-558296

F. Fakhouri, M. Jablonski, J. Lepercq, J. Blouin, A. Benachi et al., Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome, Blood, vol.112, issue.12, pp.4542-4545, 2008.
DOI : 10.1182/blood-2008-03-144691

F. Crovetto, N. Borsa, B. Acaia, C. Nishimura, K. Frees et al., The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome, The Journal of Maternal-Fetal & Neonatal Medicine, vol.26, issue.11, pp.2322-2325, 2012.
DOI : 10.1159/000078679

P. Coppo, A. Veyradier, M. Monge, and T. Rdedm, Purpura thrombotique thrombocytop??nique acquis idiopathique, La Presse M??dicale, vol.35, issue.12, pp.1876-1886, 2006.
DOI : 10.1016/S0755-4982(06)74920-X

P. Coppo, M. Wolf, A. Veyradier, A. Bussel, S. Malot et al., Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura, British Journal of Haematology, vol.138, issue.1, pp.66-74, 2006.
DOI : 10.1182/blood-2003-11-4035

URL : https://hal.archives-ouvertes.fr/hal-00453285

M. Moatti-cohen, C. Garrec, M. Wolf, P. Boisseau, L. Galicier et al., Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura, Blood, vol.119, issue.24, pp.5888-5897
DOI : 10.1182/blood-2012-02-408914

A. Veyradier, B. Obert, A. Houllier, D. Meyer, and J. Girma, Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases, Blood, vol.98, issue.6, pp.1765-1772, 2001.
DOI : 10.1182/blood.V98.6.1765

P. Mannucci, M. Canciani, I. Forza, F. Lussana, A. Lattuada et al., Changes in health and disease of the metalloprotease that cleaves von Willebrand factor, Blood, vol.98, issue.9, pp.2730-2735, 2001.
DOI : 10.1182/blood.V98.9.2730

A. Loof, H. Van-vliet, and M. Kappers-klunne, Correspondence. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura, British Journal of Haematology, vol.93, issue.4, pp.1087-1088, 2001.
DOI : 10.1056/NEJM199811263392203

A. Lattuada, E. Rossi, C. Calzarossa, R. Candolfi, and P. Mannucci, Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome, Haematologica, vol.88, pp.1029-1034, 2003.

D. Angelo, A. Fattorini, A. Crippa, and L. , Thrombotic microangiopathy in pregnancy, Thrombosis Research, vol.123, issue.2, pp.56-62, 2009.
DOI : 10.1016/S0049-3848(09)70012-X

F. Fakhouri, C. Vercel, and V. Frémeaux-bacchi, Obstetric Nephrology: AKI and Thrombotic Microangiopathies in Pregnancy, Clinical Journal of the American Society of Nephrology, vol.7, issue.12, pp.2100-2106, 2012.
DOI : 10.2215/CJN.13121211

J. George, C. Nester, and J. Mcintosh, Syndromes of thrombotic microangiopathy associated with pregnancy, Hematology, vol.2015, issue.1, pp.644-648, 2015.
DOI : 10.1182/asheducation-2015.1.644

R. Chandran, V. Serra-serra, and C. Redman, Spontaneous resolution of pre-eclampsia-related thrombocytopenia, BJOG: An International Journal of Obstetrics and Gynaecology, vol.142, issue.11, pp.887-890, 1992.
DOI : 10.1016/0002-9378(90)90376-I

K. Hovinga, J. Vesely, S. Terrell, D. Lämmle, B. George et al., Survival and relapse in patients with thrombotic thrombocytopenic purpura, Blood, vol.115, issue.8, pp.1500-1511, 2010.
DOI : 10.1182/blood-2009-09-243790

URL : http://www.bloodjournal.org/content/bloodjournal/115/8/1500.full.pdf

B. Koehl, O. Boyer, N. Biebuyck-gougé, M. Kossorotoff, V. Frémeaux-bacchi et al., Neurological involvement in a child with atypical hemolytic uremic syndrome, Pediatric Nephrology, vol.3, issue.12, pp.2539-2542, 2010.
DOI : 10.1007/s00247-004-1289-2

M. Frimat, M. Decambron, C. Lebas, A. Moktefi, L. Lemaitre et al., Renal Cortical Necrosis in Postpartum Hemorrhage: A Case Series, American Journal of Kidney Diseases, vol.68, issue.1, pp.50-57, 2016.
DOI : 10.1053/j.ajkd.2015.11.022

M. Kaplan, Eculizumab (Alexion), Curr Opin Investig Drugs, vol.3, pp.1017-1023, 2002.

G. Rock, K. Shumak, N. Buskard, V. Blanchette, J. Kelton et al., Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura, New England Journal of Medicine, vol.325, issue.6, pp.393-397, 1991.
DOI : 10.1056/NEJM199108083250604

L. Nguyen, X. Li, D. Duvall, D. Terrell, S. Vesely et al., Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, Transfusion, vol.48, pp.349-357, 1989.

M. Scully, M. Thomas, M. Underwood, H. Watson, K. Langley et al., Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes, Blood, vol.124, issue.2, pp.211-219, 2014.
DOI : 10.1182/blood-2014-02-553131

URL : http://www.bloodjournal.org/content/bloodjournal/124/2/211.full.pdf

M. Thomas, S. Robinson, and M. Scully, How we manage thrombotic microangiopathies in pregnancy, British Journal of Haematology, vol.8, issue.9, pp.821-830, 2016.
DOI : 10.1136/bmj.322.7294.1089

C. Balduini, L. Gugliotta, M. Luppi, L. Laurenti, C. Klersy et al., High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study, Annals of Hematology, vol.93, issue.6, pp.591-596, 2010.
DOI : 10.1007/s00277-009-0877-5

URL : https://hal.archives-ouvertes.fr/hal-00494349

F. Fakhouri, J. Vernant, A. Veyradier, M. Wolf, G. Kaplanski et al., Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases, Blood, vol.106, issue.6, pp.1932-1937, 2005.
DOI : 10.1182/blood-2005-03-0848

A. Froissart, M. Buffet, A. Veyradier, P. Poullin, F. Provôt et al., Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center, Critical Care Medicine, vol.40, issue.1, pp.104-111, 2012.
DOI : 10.1097/CCM.0b013e31822e9d66

M. Hull and Q. Eichbaum, Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura, Clin Adv Hematol Oncol, vol.4, pp.210-214, 2006.

A. Vazquez-mellado, M. Pequeño-luévano, O. Cantu-rodriguez, L. Villarreal-martínez, J. Jaime-pérez et al., More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura, Hematology, vol.21, issue.5, pp.311-316, 2016.
DOI : 10.1182/blood-2014-10-559211

E. Page, K. Hovinga, J. Terrell, D. Vesely, S. George et al., Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura, Blood, vol.127, issue.24, pp.3092-3094, 2016.
DOI : 10.1182/blood-2016-03-703827

K. Hyrich and S. Verstappen, Biologic therapies and pregnancy: the story so far, Rheumatology, vol.53, issue.8, pp.1377-1385, 2014.
DOI : 10.1093/rheumatology/ket409

S. Cataland and H. Wu, Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use, Journal of Thrombosis and Haemostasis, vol.119, issue.1, pp.223-229, 2015.
DOI : 10.1182/blood-2011-12-399501

URL : http://onlinelibrary.wiley.com/doi/10.1111/jth.12934/pdf

P. Jilma-stohlawetz, J. Gilbert, M. Gorczyca, P. Knöbl, and B. Jilma, A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura, Thrombosis and Haemostasis, vol.106, issue.3, pp.539-547, 2011.
DOI : 10.1160/TH11-02-0069

S. Cataland, F. Peyvandi, P. Mannucci, B. Lämmle, K. Hovinga et al., Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura, American Journal of Hematology, vol.87, issue.4, 2012.
DOI : 10.1002/ajh.23106

F. Peyvandi, M. Scully, K. Hovinga, J. Cataland, S. Knöbl et al., Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, New England Journal of Medicine, vol.374, issue.6, pp.511-522, 2016.
DOI : 10.1056/NEJMoa1505533

URL : http://boris.unibe.ch/79315/1/JKH_M.Mansouri_16021105_Caplacizumab%20for%20Acquired%20Thrombotic%20Thrombocytopenic.pdf

K. Hovinga, J. Coppo, P. Lämmle, B. Moake, J. Miyata et al., Thrombotic thrombocytopenic purpura, Nature Reviews Disease Primers, vol.93, p.17020, 2017.
DOI : 10.1182/blood-2009-12-258780

A. Eskazan, Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura, Annals of Hematology, vol.30, issue.24, pp.1751-1756, 2016.
DOI : 10.1200/JCO.2011.39.6820

A. Rottenstreich, S. Hochberg-klein, D. Rund, and Y. Kalish, The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura, Journal of Thrombosis and Thrombolysis, vol.54, issue.25, pp.678-683, 2016.
DOI : 10.3109/00365519409088566

D. Sousa-amorim, E. Blasco, M. Quintana, L. Sole, M. De-cordoba et al., Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management, Journal of Nephrology, vol.64, issue.159, pp.641-645, 2015.
DOI : 10.1053/j.ajkd.2014.01.434

G. Ardissino, S. Testa, I. Possenti, F. Tel, F. Paglialonga et al., Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 Cases, American Journal of Kidney Diseases, vol.64, issue.4, pp.633-637, 2014.
DOI : 10.1053/j.ajkd.2014.01.434